RUNX1 and acute myeloid leukemia: These features are thus used for classification of patients into different risk groups with the low-risk groups AML patients primarily characterized by presence of t(8;21)/RUNX1-RUNX1T1, t(15;17)/PML-RARA, inv(16)/CBFB-MYH11, NPM1 and CEBPA mutations; and high-risk group AML characterized by presence of features such as inv(3)/GATA2/EV1, t(5;11)/NUP98-NSD1, del(5q), monosomy 7, complex karyotype, ASXL, FLT3-ITD, MLL-PTD and RUNX1 mutations.